- Home
- ZLAB vs HCC Comparison
ZLAB vs HCC Comparison
Compare ZLAB & HCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- HCC
- Stock Information
- Founded
- ZLAB 2013
- HCC 2015
- Country
- ZLAB China
- HCC United States
- Employees
- ZLAB N/A
- HCC N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- HCC Coal Mining
- Sector
- ZLAB Health Care
- HCC Energy
- Exchange
- ZLAB Nasdaq
- HCC Nasdaq
- Market Cap
- ZLAB 3.4B
- HCC 2.8B
- IPO Year
- ZLAB 2017
- HCC 2017
- Fundamental
- Price
- ZLAB $33.78
- HCC $46.22
- Analyst Decision
- ZLAB Strong Buy
- HCC Strong Buy
- Analyst Count
- ZLAB 3
- HCC 5
- Target Price
- ZLAB $55.00
- HCC $75.00
- AVG Volume (30 Days)
- ZLAB 752.8K
- HCC 755.0K
- Earning Date
- ZLAB 02-27-2025
- HCC 02-13-2025
- Dividend Yield
- ZLAB N/A
- HCC 0.69%
- EPS Growth
- ZLAB N/A
- HCC N/A
- EPS
- ZLAB N/A
- HCC 4.79
- Revenue
- ZLAB $355,748,000.00
- HCC $1,525,220,000.00
- Revenue This Year
- ZLAB $49.04
- HCC $4.64
- Revenue Next Year
- ZLAB $46.80
- HCC $11.97
- P/E Ratio
- ZLAB N/A
- HCC $9.65
- Revenue Growth
- ZLAB 35.01
- HCC N/A
- 52 Week Low
- ZLAB $13.48
- HCC $45.94
- 52 Week High
- ZLAB $36.60
- HCC $75.53
- Technical
- Relative Strength Index (RSI)
- ZLAB 79.95
- HCC 30.42
- Support Level
- ZLAB $30.61
- HCC $52.27
- Resistance Level
- ZLAB $33.00
- HCC $50.81
- Average True Range (ATR)
- ZLAB 1.32
- HCC 2.19
- MACD
- ZLAB 0.58
- HCC -0.48
- Stochastic Oscillator
- ZLAB 86.34
- HCC 2.99
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.